Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Personalis (PSNL) Stock Price & Analysis
431 Followers
PSNL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $2.43
Previous Close$1.66
Volume254.41K
Average Volume (3M)287.77K
Market Cap
$86.22M
Enterprise Value$10.36M
Total Cash (Recent Filing)$114.18M
Total Debt (Recent Filing)$38.32M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Aug 07, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding51,938,839
10 Day Avg. Volume221,459
30 Day Avg. Volume287,768
Standard Deviation0.21
R-Squared0.22
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.49
Price to Sales (P/S)0.86
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.14
Enterprise Value/Gross Profit0.57
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$5.00Price Target Upside210.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Personalis News
Bulls Say, Bears Say
Bulls Say
Market DemandDemand for its NeXT Personal Dx offering is outstripping its early access supply, showcasing high interest and potential for growth.
Product LaunchThe recent clinical launch of NeXT Personal Dx into the minimal residual disease (MRD) testing market sets the stage for adoption by the oncology community.
Revenue GrowthPersonalis reported 1Q24 revenues of $19.5M, above analyst estimates, indicating strong financial performance.
Bears Say
Financial PerformanceRevenue growth slowed to 4% Y/Y in 1Q24 from 18% in 4Q23 as Oncology growth and V A MVP revenue growth both slowed.
Market SentimentThe substantive changes implemented by the Company have not, in the opinion of analysts, been reflected in shares which have traded down 48% since Chris Hall’s installation as CEO.
Product CommercializationA modestly discounted multiple relative to comparable companies is warranted given the early stage of the Company’s transformation toward the commercialization of NeXT Personal Dx, the pending readouts of critical NeXT Personal Dx clinical data, and the lack of reimbursement for NeXT Personal Dx.
---
Ownership Overview
29.79% Insiders
12.91% Mutual Funds
36.94% Other Institutional Investors
20.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $0.89 and its highest was $2.43 in the past 12 months.
What is Personalis Inc’s market cap?
Currently, no data Available
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Aug 07, 2024 which is in 22 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on May 08, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.147.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -$0.37.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 51,938,840 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went up 5.769%.
Which hedge fund is a major shareholder of Personalis Inc?
Among the largest hedge funds holding Personalis Inc’s share is ARK Investment Management LLC. It holds Personalis Inc’s shares valued at 9M.
---
Personalis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (210.56% Upside)
$5.00 (210.56% Upside)
Hedge Fund Trend
Decreased
By 606.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.82%
12-Months-Change
Fundamentals
Return on Equity
-58.92%
Trailing 12-Months
Asset Growth
-28.25%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
---
PSNL Earnings Call
Q1 2024
0:00 / 0:00
---
PSNL Stock 12 Month Forecast
Average Price Target
$5.00
▲(210.56% Upside)
Technical Analysis
Best Analysts Covering PSNL
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-5.54%
reiterated a buy rating 26 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -5.54% per trade.
---